npr.org
This drug is a true gamechanger
In the SURMOUNT-1 study, people who took the highest dose of tirzepatide, most of whom had a BMI of about 30 or higher but did not have diabetes, lost about 21% of their body weight during the 72 week study. As researchers point out, for people who have bariatric surgery, typical weight loss is about 25% to 30% of their weight, one or two years after the surgery. In the tirzepatide study, 36% of people taking the highest dose lost 25% or more of their body weight.
this is comparable to bariatric surgery
Jump in the discussion.
No email address required.
Notes -
Cancer treatment is extremely expensive and cancer patients (especially those caught after Stage I) are often medicalized for life even in the cases where they live for decades afterward.
Moreover what does the duration of the treatment matter? Why should the pharma company's incentives be different as between a therapeutic that is extremely expensive over the short term and a therapeutic that is moderately expensive over the long term, if the NPVs are the same?
Shouldn't your theory predict, for example, that pharma companies selling expensive therapeutics for lung cancer should oppose smoking cessation efforts?
They wouldn't do that because it would be so obvious conflict of interest that the outrage would follow and the government would simply shut the company or fined them billions.
We have done this to companies for much smaller conflicts of interests. For example, the company that misleadingly advertised opioids as non-addictive got liquidated (https://en.wikipedia.org/wiki/Purdue_Pharma).
More options
Context Copy link
More options
Context Copy link